Immunogenicity of a 2-Dose Regimen of Moderna Mrna Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.

Nadine G. Rouphael,Angela R. Branche,David J. Diemert,Ann R. Falsey, Cecilia Losada,Lindsey R. Baden,Sharon E. Frey,Jennifer A. Whitaker,Susan J. Little, Satoshi Kamidani,Emmanuel B. Walter,Richard M. Novak,Richard Rupp,Lisa A. Jackson,Tara M. Babu,Angelica C. Kottkamp, Anne F. Luetkemeyer,Lilly C. Immergluck,Rachel M. Presti,Martin Backer,Patricia L. Winokur,Siham M. Mahgoub, Paul A. Goepfert, Dahlene N. Fusco,Robert L. Atmar,Christine M. Posavad,Antonia Netzl,Derek J. Smith,Kalyani Telu,Jinjian Mu, Lisa J. McQuarrie,Mat Makowski,Mamodikoe K. Makhene,Sonja Crandon,David C. Montefiori, Paul C. Roberts,John H. Beigel, Kuleni Abebe

JOURNAL OF INFECTIOUS DISEASES（2023）

引用 0|浏览13

暂无评分

摘要

We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen with a variant vaccine did not increase the magnitude or the durability of the serological responses compared to a single variant vaccine boost.

查看译文

关键词

SARS-CoV-2,vaccine,variant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要